#2 - Pfizer (NYSE:PFE)
Pfizer (PFE) and BioNTech SE (BNTX) - On the vaccine front, Pfizer (NYSE:PFE) announced a deal with the German company BioNTech SE (NASDAQ:BNTX) to co-develop and distribute a vaccine candidate for the coronavirus. Pfizer will be using BioNTech’s mRNA-based drug development platform. The agreement will exclude distribution in China. The plan is for the vaccine to go into U.S. and German clinical trials in late April.
The coronavirus vaccine is the latest example of the partnership between the two companies who have worked together in the past to develop mRNA-based influenza vaccines.
Leveraging expertise and resources of both companies" said BioNTech and Pfizer in a statement, the "collaboration aims to accelerate global development of BNT162," with cooperation beginning immediately, and clinical testing to begin in late April 2020. From start of testing to eventual approval (one hopes), could take perhaps 12 to 18 months.
Separately, BioNTech also made a deal to collaborate with Shanghai Fosun Pharmaceutical on an experimental vaccine that will be begin human testing in China in April.
Shares of BioNTech are up 54% for the year. Pfizer stock is down over 20% in 2020.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $28.93
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $35.86 (23.9% Upside)
